Look back at some of the important news and notes from last week you might have missed in the world of oncology. The FDA granted priority review to zanubrutinib, while 2 features from the journal ONCOLOGY® published on belantamab mafodotin and renal cell carcinoma, respectively, were popular with readers.
Each Monday, CancerNetwork® highlights the most important content from the previous week in oncology news.
The top articles from last week focused on the FDA granting priority review to zanubrutinib in pretreat patients with marginal zone lymphoma, and 2 journal ONCOLOGY® articles examining the product profile of balantamab mafodotin and a Clinical Quandaries segment on renal cell carcinoma.
The results from a trial evaluating the Genomic Prostate Score did not find an increase in active surveillance acceptance amongst a population of predominantly Black men with favorable-risk prostate cancer.
More, active surveillance acceptance for managing patients with this disease was high overall regardless of race and for patients who received either the GPS assay or conventional risk counseling.
The combination of alpelisib (Piqray) and fulvestrant maintained a tolerable safety profile for patients with PIK3CA-mutated, hormone receptor–positive, HER2-negative advanced breast cancer who progressed after previous treatment with a CDK4/6 inhibitor.
The ongoing, multicenter, open-label, phase 2 BYLieve trial (NCT03056755) assessed both safety and activity of the combination of alpelisib plus either letrozole (Femara) or fulvestrant to treat patients with this type of HER2-negative advanced breast cancer.
Based on phase 1 and 2 trial results and pooled safety data from several clinical trials, zanubrutinib (Brukinsa) moves forward with a priority review in relapsed/refractory marginal zone lymphoma.
Currently, zanubrutinib is approved by the FDA as therapy for patients with mantle cell lymphoma who have received at least 1 prior therapy and is being explored across other hematologic malignancies. The safety data for the current application is also based on pooled data from 847 patients with B-cell malignancies across 7 clinical trials.
Kathryn Maples, PharmD, BCOP, discusses real-world implications of belantamab mafodotin in patients with pretreated multiple myeloma.
“Belantamab mafodotin is a first-in-class, novel antibody-drug conjugate. It is an antibody targeting BCMA [B-cell maturation antigen], which is expressed on multiple myeloma cells.”
Another installment of Clinical Quandaries is presented by Karen Férez-Blando, MD, and colleagues of a 45-year-old man with a diagnosis of intermediate-risk stage IV clear cell renal carcinoma who develops grade 2 hand-foot skin reaction on sunitinib therapy.